Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedJan 02, 2026
DataAggregated Company Financials
Companies151
  • 7D0.8%
  • 3M-4.6%
  • 1Y-7.5%
  • YTDn/a

Over the last 7 days, the Healthcare industry has remained flat. Unfortunately though, the industry is down 7.7% over the past 12 months. Looking forward, earnings are forecast to grow by 27% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 02 Jan 2026SEK 588.5bSEK 230.5bSEK 3.7b42.2x160.1x2.6x
Sun, 30 Nov 2025SEK 606.1bSEK 230.8bSEK 3.6b42.7x168.5x2.6x
Tue, 28 Oct 2025SEK 642.6bSEK 228.1bSEK 3.5b47.9x185.4x2.8x
Thu, 25 Sep 2025SEK 602.0bSEK 227.2bSEK 6.6b43.7x91.1x2.6x
Sat, 23 Aug 2025SEK 630.3bSEK 227.2bSEK 6.3b48x100x2.8x
Mon, 21 Jul 2025SEK 630.5bSEK 227.7bSEK 6.6b46.7x94.9x2.8x
Wed, 18 Jun 2025SEK 599.5bSEK 226.4bSEK 5.8b39.4x102.9x2.6x
Fri, 16 May 2025SEK 606.2bSEK 224.9bSEK 5.6b35.4x108x2.7x
Sun, 13 Apr 2025SEK 527.1bSEK 221.7bSEK 5.4b31.8x96.9x2.4x
Tue, 11 Mar 2025SEK 547.4bSEK 206.0bSEK 4.7b35.7x116.6x2.7x
Thu, 06 Feb 2025SEK 597.4bSEK 203.8bSEK 1.6b42.7x379.9x2.9x
Sat, 04 Jan 2025SEK 588.1bSEK 202.6b-SEK 2,502,717,854.4140.4x-235x2.9x
Mon, 02 Dec 2024SEK 516.5bSEK 199.4b-SEK 2,781,058,821.9737.7x-185.7x2.6x
Wed, 30 Oct 2024SEK 543.4bSEK 198.8b-SEK 2,731,632,105.0037.1x-198.9x2.7x
Fri, 27 Sep 2024SEK 619.2bSEK 200.0b-SEK 2,815,781,310.2638.8x-219.9x3.1x
Sun, 25 Aug 2024SEK 605.5bSEK 200.0b-SEK 2,323,183,060.9437.7x-260.6x3x
Tue, 23 Jul 2024SEK 596.1bSEK 198.6b-SEK 2,821,682,071.1744.3x-211.2x3x
Thu, 20 Jun 2024SEK 548.6bSEK 195.4b-SEK 3,181,881,906.1535.5x-172.4x2.8x
Sat, 18 May 2024SEK 549.2bSEK 196.6b-SEK 2,628,506,460.6037x-208.9x2.8x
Mon, 15 Apr 2024SEK 520.3bSEK 192.9b-SEK 3,176,124,769.5445.5x-163.8x2.7x
Wed, 13 Mar 2024SEK 530.2bSEK 192.1b-SEK 3,677,406,617.4443.9x-144.2x2.8x
Fri, 09 Feb 2024SEK 517.6bSEK 190.8b-SEK 4,350,958,868.3150.3x-119x2.7x
Sun, 07 Jan 2024SEK 537.1bSEK 191.4b-SEK 966,074,470.0046.6x-555.9x2.8x
Tue, 05 Dec 2023SEK 502.4bSEK 190.5b-SEK 1,085,960,442.0051.7x-462.6x2.6x
Thu, 02 Nov 2023SEK 443.8bSEK 189.4b-SEK 1,110,680,428.0038.3x-399.5x2.3x
Sat, 30 Sep 2023SEK 450.7bSEK 184.9b-SEK 2,031,625,350.0035.4x-221.8x2.4x
Mon, 28 Aug 2023SEK 461.2bSEK 185.8b-SEK 1,790,799,672.0037.7x-257.5x2.5x
Wed, 26 Jul 2023SEK 479.4bSEK 182.6b-SEK 997,603,274.0041.4x-480.5x2.6x
Fri, 23 Jun 2023SEK 483.2bSEK 179.1b-SEK 795,874,311.0043.6x-607.2x2.7x
Sun, 21 May 2023SEK 525.7bSEK 177.4b-SEK 874,267,530.0043x-601.3x3x
Tue, 18 Apr 2023SEK 511.6bSEK 172.5b-SEK 1,420,278,814.0035.3x-360.2x3x
Thu, 16 Mar 2023SEK 479.0bSEK 172.3b-SEK 1,402,563,401.0035.8x-341.5x2.8x
Sat, 11 Feb 2023SEK 508.6bSEK 169.1bSEK 473.1m34x1075.1x3x
Mon, 09 Jan 2023SEK 476.6bSEK 165.7bSEK 699.2m32.4x681.6x2.9x
Price to Earnings Ratio

681.6x


Total Market Cap: SEK 476.6bTotal Earnings: SEK 699.2mTotal Revenue: SEK 165.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -132.8x202420252026
Current Industry PE
  • Investors are optimistic on the Swedish Healthcare industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 160x which is higher than its 3-year average PE of -132x.
  • The industry is trading close to its 3-year average PS ratio of 2.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 74% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market1.25%
Healthcare0.78%
Pharma1.63%
Medical Equipment1.47%
Healthcare Services0.62%
Biotech0.48%
Healthtech-0.06%
Life Sciences-0.60%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 123x.
    • Analysts are expecting annual earnings growth of 17.5%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Healthtech industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GETI B GetingeSEK 218.802.6%
+SEK 1.5b		20.5%PE29x
SOBI Swedish Orphan BiovitrumSEK 332.801.0%
+SEK 1.2b		4.4%PE8823.2x
CAMX CamurusSEK 616.001.6%
+SEK 566.6m		4.5%PE47x
BONEX Bonesupport HoldingSEK 188.003.7%
+SEK 441.3m		-53.0%PE81.5x
VIMIAN Vimian GroupSEK 30.342.6%
+SEK 401.8m		-23.1%PE47.1x

Latest News

BIOG B
SEK 106.20
BioGaia
7D
3.7%
1Y
-4.0%
BIOA B
SEK 310.80
BioArctic
7D
-2.9%
1Y
46.6%

BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks

Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.
VITR
SEK 137.00
Vitrolife
7D
-0.7%
1Y
-37.0%

VITR: Restructuring And Goodwill Impairment Will Support Future Upside Potential

Analysts have slightly reduced their price target on Vitrolife, trimming fair value by SEK 4.75 to SEK 188.75, as modestly higher long term growth assumptions are offset by a small downgrade to profitability and a lower expected valuation multiple. What's in the News Vitrolife plans to record a SEK 5.4 billion goodwill impairment in the fourth quarter of 2025 related to the Igenomix acquisition (company announcement).
VIMIAN
SEK 30.34
Vimian Group
7D
2.6%
1Y
-23.1%
ALIF B
SEK 159.10
AddLife
7D
-2.0%
1Y
15.4%

ALIF B Stable Margins And Discount Rate Will Support Future Upside Potential

Analysts have slightly reduced their price target on AddLife by SEK 5 to SEK 208.50, citing a modestly higher discount rate, somewhat softer long term revenue growth assumptions, and a marginally lower profit margin outlook, partly offset by a small increase in expected future valuation multiples. Valuation Changes The fair value estimate has fallen slightly from SEK 213.50 to SEK 208.50.
BONEX
SEK 188.00
Bonesupport Holding
7D
3.7%
1Y
-53.0%

BONEX: De Novo Pathway Shift Will Support Strong Future Market Position

Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.
STIL
SEK 196.00
Stille
7D
-5.8%
1Y
-4.4%

Returns At Stille (STO:STIL) Are On The Way Up

Dec 23
Returns At Stille (STO:STIL) Are On The Way Up
CAMX
SEK 616.00
Camurus
7D
1.6%
1Y
4.5%

CAMX: Positive Obesity Data Will Drive Future Upside Potential

Narrative Update on Camurus Analysts have modestly raised their price target on Camurus to reflect a fair value of approximately SEK 794 per share, citing sustained strong revenue growth expectations and robust long term profit margins as key drivers of the upward revision. What's in the News Reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide, showing dose dependent reductions in body weight, A1c, and fasting glucose that were comparable to or exceeded weekly semaglutide, with similar or better efficacy in a shorter treatment period (Key Developments).
SECT B
SEK 251.00
Sectra
7D
-0.4%
1Y
-8.6%

SECT B: Cloud Expansion Will Support Earnings Multiples Amid Balanced Risk

Analysts have raised their price target on Sectra from SEK 207.5 to SEK 245.0, citing slightly stronger long term revenue growth assumptions and a higher expected future earnings multiple, partly offset by a marginally lower profit margin outlook. What's in the News Sectra will provide a unified Sectra One Cloud enterprise imaging solution for four NHS trusts in Lancashire and South Cumbria, consolidating radiology and breast imaging across 15 hospitals to strengthen cybersecurity and collaboration (Client Announcements).
HNSA
SEK 34.36
Hansa Biopharma
7D
10.0%
1Y
-13.7%
SUBGEN
SEK 0.97
Subgen AI
7D
-22.0%
1Y
n/a
GETI B
SEK 218.80
Getinge
7D
2.6%
1Y
20.5%
CURAS
DKK 11.10
Curasight
7D
-17.8%
1Y
11.4%
SOBI
SEK 332.80
Swedish Orphan Biovitrum
7D
1.0%
1Y
4.4%

SOBI: Rare Disease Pipeline Progress Will Drive Future Share Price Upside

Analysts have raised their price target on Swedish Orphan Biovitrum from SEK 360 to SEK 367, reflecting slightly improved fair value assumptions and confidence in the company’s future earnings backed by recent positive research commentary. Analyst Commentary Recent upgrades reflect a growing conviction that Swedish Orphan Biovitrum can deliver attractive risk adjusted returns at current levels, with the new SEK 370 price target signaling modest upside from the revised fair value range.
ASKER
SEK 84.40
Asker Healthcare Group
7D
-1.2%
1Y
n/a
IMP A SDB
SEK 50.10
Implantica
7D
2.9%
1Y
46.3%